Researchers from the Department of Biochemistry and NUS Centre for Cancer Research (N2CR), at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have been pioneering a treatment using stem ...
Jul 10, 2024
0
2
A new research paper was published in Oncotarget titled, "Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling ...
Jul 9, 2024
0
0
Teams at two of Melbourne's leading research and medical institutes are developing high-tech solutions to rapidly test for drugs and better treat patients presenting to hospital.
Jul 5, 2024
0
0
An editorial paper was published in Oncoscience on May 20, 2024, titled, "Deep learning-assisted lesion segmentation in PET/CT imaging: A feasibility study for salvage radiation therapy in prostate cancer."
Jul 1, 2024
0
1
Despite high hopes, a drug that wipes out the namesake cell type associated with the disease eosinophilic esophagitis (EoE) doesn't make patients feel better and doesn't reverse tissue damage in their throats.
Jun 27, 2024
0
12
A new study from Karolinska Institutet shows that 45 genes may play a crucial role in the prognosis of patients with adrenal cancer. The findings, published in the journal ESMO Open, give hope for a better diagnostic tool ...
Jun 27, 2024
0
0
Ovarian cancer, often diagnosed at an advanced stage, presents significant treatment challenges because patients tend to develop resistance to conventional therapies quickly. Despite aggressive treatment, recurrence rates ...
Jun 26, 2024
0
0
The nuclear protein Ki67 is a meaningful biomarker for tumor aggressiveness and for the success of surgical therapy in pleural mesothelioma, a malignant disease of the pleura. This is the clear and promising result of an ...
Jun 26, 2024
0
0
Type 2 diabetes in young people ages 10 to19 has more than doubled in the past 20 years, yet it remains difficult for physicians to predict who will be diagnosed and who will improve with treatment. A study from the University ...
Jun 24, 2024
0
4
The U.S. Food and Drug Administration has expanded indications for AbbVie's Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic ...
Jun 24, 2024
0
0
